Top

Strahlentherapie und Onkologie

Published in:

01-03-2016 | Original Article

Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

Authors: P. M. Putora, D. Engeler, S. R. Haile, N. Graf, K. Buchauer, H. P. Schmid, L. Plasswilm

Published in: Strahlentherapie und Onkologie | Issue 3/2016

Abstract

Background and purpose

For localized prostate cancer, treatment options include external beam radiotherapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT). Erectile dysfunction (ED) is a common side-effect. Our aim was to evaluate penile erectile function (EF) before and after BT, EBRT, or RP using a validated self-administered quality-of-life survey from a prospective registry.

Material and methods

Analysis included 478 patients undergoing RP (n = 252), EBRT (n = 91), and BT (n = 135) with at least 1 year of follow-up and EF documented using IIEF-5 scores at baseline, 6 weeks, 6 months, 1 year, and annually thereafter.

Results

Differences among treatments were most pronounced among patients with no or mild initial ED (IIEF-5 ≥ 17). Overall, corrected for baseline EF and age, BT was associated with higher IIEF-5 scores than RP (+ 7.8 IIEF-5 score) or EBRT (+ 3.1 IIEF-5 score). EBRT was associated with better IIEF-5 scores than RP (+ 4.7 IIEF-5 score). In patients undergoing EBRT or RP with bilateral nerve sparing (NS), recovery of EF was observed and during follow-up, the differences to BT were not statistically significant. Overall age had a negative impact on EF preservation (corrected for baseline IIEF).

Conclusion

In our series, EF was adversely affected by each treatment modality. Considered overall, BT provided the best EF preservation in comparison to EBRT or RP.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30CrossRefPubMed

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448CrossRefPubMed

Eble MJ (2014) Bevölkerungsbasierte Analyse von Komplikationen nach lokaler Therapie des Prostatakarzinoms. Strahlenther Onkol 190:594–596CrossRefPubMed

Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL (2003) General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21:1147–1154CrossRefPubMed

Valicenti RK, Bissonette EA, Chen C, Theodorescu D (2002) Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol 168:2499–2504 (discussion 2504). doi:10.1097/01.ju.0000038153.45342.57 CrossRefPubMed

Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP (2009) Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 82:17–23. doi:10.1159/000176019 CrossRefPubMed

Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC (2003) Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 44:656–660CrossRefPubMed

Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445. doi:10.1056/NEJMoa1209978 PubMedCentralCrossRefPubMed

Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology G (2008) Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112–120. doi:10.1200/JCO.2006.10.4505 CrossRefPubMed

10.

Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 191:338–348CrossRefPubMed

11.

Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P (2015) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. doi:10.1111/bju.13179

12.

Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61:664–675. doi:10.1016/j.eururo.2011.11.053 CrossRefPubMed

13.

Anandadas CN, Clarke NW, Davidson SE, O’Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA, North West Uro-oncology G (2011) Early prostate cancer–which treatment do men prefer and why? BJU Int 107:1762–1768. doi:10.1111/j.1464-410X.2010.09833.x CrossRefPubMed

14.

Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830CrossRefPubMed

15.

Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326CrossRefPubMed

16.

Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca JI, Mandhani A, Tewari A (2007) Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sex Med 4:1336–1344CrossRefPubMed

17.

Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70

18.

R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

19.

Bates D Mächler M, Bolker B (2013) lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-2

20.

Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in General Parametric Models. Biom J 50:346–336CrossRefPubMed

21.

van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111:564–573. doi:10.1111/j.1464-410X.2012.11402.x CrossRefPubMed

22.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261. doi:10.1056/NEJMoa074311 CrossRefPubMed

23.

Magheli A, Burnett AL (2009) Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 6:415–427. doi:10.1038/nrurol.2009.126 CrossRefPubMed

24.

Glickman L, Godoy G, Lepor H (2009) Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol 181:731–735. doi:10.1016/j.juro.2008.10.019 CrossRefPubMed

25.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.1056/NEJMoa1113162 PubMedCentralCrossRefPubMed

26.

Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Buttner H (2014) Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a Randomised Placebo-controlled Study (REACTT). Eur Urol 65:587–596. doi:10.1016/j.eururo.2013.09.051 CrossRefPubMed

27.

Turner SL, Adams K, Bull CA, Berry MP (1999) Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 54:124–129CrossRefPubMed

28.

Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468CrossRefPubMed

29.

van der Wielen GJ, Mulhall JP, Incrocci L (2007) Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol 84:107–113. doi:10.1016/j.radonc.2007.07.018 CrossRefPubMed

30.

Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235–1242CrossRefPubMed

31.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:437–447. doi:10.1016/j.ijrobp.2004.10.001 CrossRefPubMed

32.

Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69:338–342. doi:10.1016/j.urology.2006.10.001 CrossRefPubMed

33.

Ong WL, Hindson BR, Beaufort C, Pharoah P, Millar JL (2014) Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. Radiother Oncol 112:72–76. doi:10.1016/j.radonc.2014.04.017 CrossRefPubMed

34.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH (2009) Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 75:639–648. doi:10.1016/j.ijrobp.2008.11.058 CrossRefPubMed

35.

Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ (2014) An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer. Brachytherapy 13:163–168. doi:10.1016/j.brachy.2013.10.006 CrossRefPubMed

36.

Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE (2007) Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109:2239–2247. doi:10.1002/cncr.22676 CrossRefPubMed

37.

Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, Craven-Bratle J, Suarez JF, Boladeras A, Pont A, Ayala A, Sancho G, Martinez E, Alonso J, Ferrer M (2010) Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 28:4687–4696. doi:10.1200/JCO.2009.25.3245 CrossRefPubMed

38.

Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460–463CrossRefPubMed

39.

Nishimura S, Yorozu A, Ohashi T, Sakayori M, Yagi Y, Nishiyama T, Saito S, Shiraishi Y, Yoshida K, Toya K, Shigematsu N (2013) Five-year potency preservation after iodine-125 prostate brachytherapy. Int J Clin Oncol. doi:10.1007/s10147-013-0632-8

40.

Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M (2013) A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. J Urol 189:1014–1018. doi:10.1016/j.juro.2012.09.086 CrossRefPubMed

41.

Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205–1214. doi:10.1001/jama.2011.1333 CrossRefPubMed

42.

Rizvi K, Hampson JP, Harvey JN (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19:95–98CrossRefPubMed

43.

Fonseca V, Seftel A, Denne J, Fredlund P (2004) Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 47:1914–1923CrossRefPubMed

44.

McVary KT, Carrier S, Wessells H (2001) Smoking and erectile dysfunction: evidence based analysis. J Urol 166:1624–1632CrossRefPubMed

45.

Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z (1997) Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 9:123–126CrossRefPubMed

46.

Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, Titone F, Parisi G, Fongione S (2012) Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Strahlenther Onkol 188:997–1002CrossRefPubMed

47.

Panje CM, Dal Pra A, Zilli T, D RZ, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. doi:10.1007/s00066-015-0849-8

48.

Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484. doi:10.1007/s00066-011-2249-z CrossRefPubMed

49.

van der Wielen GJ, van Putten WL, Incrocci L (2007) Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 68:479–484. doi:10.1016/j.ijrobp.2006.12.015 CrossRefPubMed

Title: Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients
Authors: P. M. Putora
D. Engeler
S. R. Haile
N. Graf
K. Buchauer
H. P. Schmid
L. Plasswilm
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 3/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0928-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

Abstract

Background and purpose

Material and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and purpose

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

Primary glioblastoma multiforme tumors and recurrence

Kardiale Toxizität von Trastuzumab in der adjuvanten Therapie von Mammakarzinompatientinnen

Langzeitergebnisse zweier verschiedener Behandlungskonzepte mit HDR-Brachytherapie-Boost bei Prostatakarzinomen mit intermediärem Risiko

Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin

Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients

Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children